# Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

> **NCT05624450** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 2870 (estimated)

## Conditions studied

- Viral Lung Infection and Acute Respiratory Failure

## Interventions

- **DRUG:** Tozorakimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05624450
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-13
- **Primary completion:** 2026-06-19
- **Final completion:** 2026-06-19
- **Target enrollment:** 2870 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624450, "Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05624450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*